For in vitro diagnostic use. Others cobas WNV Test 5800 6800 8800 IVD cobas® WNV Test PID00000371 Nucleic acid test for use on the cobas® 5800/6800/8800 systems 09 171 142 190 9 171 142 190 09171142190 9171142190 09171142190 KIT COBAS 58/68/8800 WNV 192T CE-IVD KIT COBAS 58/68/8800 WNV 192T CE-IVD 00875197006711 Reagents, kits 1 pack 192 tests true 09 040 927 190 9 040 927 190 09040927190 9040927190 09040927190 KIT COBAS 58/68/8800 WNV 480T IVD KIT COBAS 58/68/8800 WNV 480T IVD 00875197006520 Reagents, kits 1 pack 480 tests true The cobas® WNV test for use on cobas® 6800 and cobas® 8800 Systems is a qualitative in vitro test for the direct detection of West Nile Virus (WNV) RNA in human plasma.This test is intended for use to screen donor samples for WNV RNA in plasma samples from individual human donors, including donors of whole blood and blood components, as well as other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor’s heart is still beating and for testing of cadaveric (non-heart beating) donors.This test is not intended for use on samples of cord blood.Plasma from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma samples may be tested individually or may be tested in pools comprised of aliquots of individual samples. For donations from cadaveric (non-heart beating) organ and tissue donors, samples may only be screened as individual sample.This test is not intended for use as an aid in diagnosis of WNV infection. en cobas® WNV for use on cobas® 6800 and cobas® 8800 Systems is a qualitative in vitro nucleic acid screening test for the direct detection of West Nile virus (WNV) RNA in human plasma.This test is intended for use to screen donor samples for WNV RNA in plasma samples from individual human donors, including donors of whole blood and blood components, as well as other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor’s heart is still beating using plasma or from cadaveric (non-heart beating) donors using plasma and serum.Plasma from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma samples may be tested individually or in pools comprised of not more than six individual samples. For all other donors, samples may only be screened as individual samples.For donations from cadaveric (non-heart-beating) organ and tissue donors, samples may only be screened as individual samples.This test is not intended for use as an aid in diagnosis of WNV infection.This test is not intended for use on samples of cord blood. en cobas® WNV for use on cobas® 6800 and cobas® 8800 Systems is a qualitative in vitro nucleic acid screening test for the direct detection of West Nile virus (WNV) RNA in human plasma.This test is intended for use to screen donor samples for WNV RNA in plasma samples from individual human donors, including donors of whole blood and blood components, as well as other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor’s heart is still beating and for testing cadaveric (non-heart beating) donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor’s heart is still beating and for testing cadaveric (non-heart beating) donorPlasma from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma samples may be tested individually or in pools comprised of not more than six individual samples. For donations from cadaveric (non-heart-beating) organ and tissue donors, samples may only be screened as individual samples.This test is not intended for use as an aid in diagnosis of WNV infection.This test is not intended for use on samples of cord blood. en cobas® WNV is based on real time PCR technology on a fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection system. The cobas® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report or sent to a Laboratory Information Management System (LIMS) or other result management system.Samples can either be tested individually or, optionally, can be tested in pools consisting of multiple samples. The cobas® Synergy software with the Hamilton MICROLAB® STAR IVD, may optionally be used in a pre-analytical step if pooling is to be performed.Nucleic acid from the sample and added armored RNA internal control (IC) (which serves as the sample preparation and amplification/detection process control) are simultaneously extracted. In addition the test utilizes two kit controls: a positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).34-36 Any contaminating amplicon from previous PCR runs are destroyed by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR mix, when heated in the first thermal cycling step. However, newly formed amplicon are not destroyed since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.cobas® WNV master mix contains detection probes which are specific for WNV and IC nucleic acid. The specific WNV and IC detection probes are each labeled with one of two unique fluorescent dyes which act as a reporter. Each probe also has a second dye which acts as a quencher. The two reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified WNV target and the IC.37,38 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the two specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified WNV target and the IC are possible.34.Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-128.35. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-493.36. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-878.37. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY). 1992;10:413-417.38. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994. en The cobas® WNV test is based on real time PCR technology on a fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection system. The cobas® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report, or sent to a Laboratory Information Management System (LIMS) or other result management system.Samples can either be tested individually or, optionally, can be tested in pools consisting of multiple samples. If pooling is to be performed, the cobas p 680 instrument, or cobas® Synergy software with the Hamilton MICROLAB® STAR /STARlet IVD, may optionally be used in a pre-analytical step if pooling is to be performed.Nucleic acid from the sample and added armored RNA internal control (IC) (which serve as the sample preparation and amplification/detection process control) is simultaneously extracted. In addition the test utilizes two kit controls: a positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).34-36 Any contaminating amplicon from previous PCR runs are destroyed by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR mix, when heated in the first thermal cycling step. However, newly formed amplicon are not destroyed since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.The cobas® WNV master mix contains detection probes which are specific for WNV and IC nucleic acid. The specific WNV and IC detection probes are each labeled with one of two unique fluorescent dyes which act as a reporter. Each probe also has a second dye which acts as a quencher. The two reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified WNV target and the IC.37,38 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the two specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified WNV target and the IC are possible.34. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-128.35. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-493.36. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-878.37. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY). 1992;10:413-417.38. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994. en cobas® WNV is based on real time PCR technology on a fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection system. The cobas® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report or sent to a Laboratory Information Management System (LIMS) or other result management system.Samples can either be tested individually or, optionally, can be tested in pools consisting of multiple samples. The cobas p 680 instrument, or cobas® Synergy software with the Hamilton MICROLAB® STAR/STARlet IVD, may optionally be used in a pre-analytical step if pooling is to be performed.Nucleic acid from the sample and added armored RNA internal control (IC) (which serve as the sample preparation and amplification/detection process control) is simultaneously extracted. In addition the test utilizes two kit controls: a positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). 34-36 Any contaminating amplicon from previous PCR runs are destroyed by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR mix, when heated in the first thermal cycling step. However, newly formed amplicon are not destroyed since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.cobas® WNV master mix contains detection probes which are specific for WNV and IC nucleic acid. The specific WNV and IC detection probes are each labeled with one of two unique fluorescent dyes which act as a reporter. Each probe also has a second dye which acts as a quencher. The two reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified WNV target and the IC. 37,38 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the two specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified WNV target and the IC are possible.34. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-128.35. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-493.36. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-878.37. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY). 1992;10:413-417.38. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994 en

User Profile

Select your user profile

cobas^® WNV Test

Détection du virus du Nil occidental dans le cadre de la qualification des dons

Détectez l'ARN du virus du Nil occidental dans le plasma humain pour un niveau de sécurité supplémentaire, et ce tout au long de l'année

Caractéristiques et avantages¹

Réduire les risques de transmission du virus par transfusion.

Vous souhaitez être recontacté ?

Description

Detailed Specifications

You might be interested in

Référence produit

Produits associés

Documents techniques

User Profile

Select your user profile

cobas® WNV Test

Détection du virus du Nil occidental dans le cadre de la qualification des dons

Détectez l'ARN du virus du Nil occidental dans le plasma humain pour un niveau de sécurité supplémentaire, et ce tout au long de l'année

Caractéristiques et avantages1

Réduire les risques de transmission du virus par transfusion.

Vous souhaitez être recontacté ?

Description

Detailed Specifications

You might be interested in

Référence produit

Produits associés

Documents techniques

cobas^® WNV Test

Caractéristiques et avantages¹